title: Guidelines on treatment of stage IIIB non-small cell lung cancer.
abstract: Stage IIIB includes patients with T4, any N, M0, and any T, N3, M0. Surgery may be indicated only for carefully selected T4N0M0 patients with or without neoadjuvant chemotherapy or chemoradiotherapy. Patients with N3 lymph node involvement are not considered as surgical candidates. For patients with unresectable disease, good performance score, and minimal weight loss, treatment with combined chemotherapy and radiotherapy has resulted in better survival than treatment with radiotherapy alone. Multiple daily fractions of radiotherapy have not resulted in improved survival compared with standard fractionation once daily. Concurrent chemoradiotherapy appears to be associated with improved survival compared with sequential chemotherapy and radiotherapy. Treatment of stage IIIB due to malignant pleural effusion is addressed in the section that deals with stage IV disease.
authors.affiliation: Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. jett.james@mayo.edu
authors.forename: James R
authors.initials: JR
authors.lastname: Jett
authors.forename: Walter J
authors.initials: WJ
authors.lastname: Scott
authors.forename: M Patricia
authors.initials: MP
authors.lastname: Rivera
authors.forename: William T
authors.initials: WT
authors.lastname: Sause
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging
chemical_list: D000970:Antineoplastic Agents